OABI - OmniAb, Inc.
About OmniAb, Inc. (https://www.omniab.com)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Matthew W. Foehr | President, Chief Executive Officer & Director | 1973 | $1,066,620 USD |
| Charles S. Berkman | Chief Legal Officer & Secretary | 1969 | $742,065 USD |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer | 1968 | $730,741 USD |
| Bill Harriman | Senior Vice President of Antibody Discovery | – | – |
| Bob Chen | Senior Vice President of Discovery Systems | – | – |
| Christel Iffland | Senior Vice President of Antibody Technologies | – | – |
| Cia McCaffrey | Senior Vice President of People & Talent | – | – |
| Todd Pettingill | Vice President of Business Development & Strategy | – | – |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research | – | – |